[Neonatal exposure to active pulmonary tuberculosis in a maternity ward: screening and clinical course of a cohort of exposed infants]

Arch Pediatr. 2012 Apr;19(4):396-403. doi: 10.1016/j.arcped.2012.01.017. Epub 2012 Feb 28.
[Article in French]

Abstract

Few data are available on the impact of a tuberculosis exposure on newborns in a maternity ward.

Objectives: To describe the screening and clinical course of infants exposed during the neonatal period to a caregiver with bacillary tuberculosis.

Patients and methods: Infants exposed during the postnatal period in a maternity unit in Paris, from March to August 2005, to a caregiver with bacillary tuberculosis were included in a standardized screening protocol. The screening performed at baseline (M0) and at 3 months (M3) included a clinical evaluation, a tuberculin skin test (TST), and a chest X-ray. A preventive treatment for tuberculosis with isoniazid and rifampicin for 3 months was systematically proposed.

Results: At M0, 182 of the 217 infants (84%) with significant exposure were evaluated. Data were available for 172 infants. The median age at M0 was 4.9 months (IQR=3.8-6.2). At M0, 4 of 172 infants (2.3%) had latent TB infection. Between M0 and M3, 19 infants (11%) were lost to follow-up and 1 on 153 developed a latent TB infection. No cases of tuberculosis disease were diagnosed. The treatment was administered properly in 83% of cases and side effects were observed in 11% of infants without any serious adverse event. Four infants received no treatment and 11 stopped their treatment prematurely.

Conclusion: In the absence of neonatal massive exposure, although low (2.9%), the risk of latent TB infection requires close monitoring of the infants exposed. However, in the context of a mild exposure in the maternity unit, surveillance without systematic initiation of TB preventive treatment could be discussed.

Publication types

  • English Abstract

MeSH terms

  • Antitubercular Agents / therapeutic use
  • Cohort Studies
  • Cross Infection / diagnosis
  • Cross Infection / prevention & control
  • Cross Infection / transmission*
  • Female
  • Follow-Up Studies
  • Humans
  • Infant
  • Infectious Disease Transmission, Professional-to-Patient*
  • Isoniazid / therapeutic use
  • Latent Tuberculosis / diagnosis
  • Latent Tuberculosis / prevention & control
  • Latent Tuberculosis / transmission*
  • Male
  • Mass Chest X-Ray
  • Mass Screening*
  • Obstetrics and Gynecology Department, Hospital
  • Paris
  • Rifampin / therapeutic use
  • Risk Factors
  • Tuberculin Test
  • Tuberculosis, Pulmonary / diagnosis
  • Tuberculosis, Pulmonary / prevention & control
  • Tuberculosis, Pulmonary / transmission*

Substances

  • Antitubercular Agents
  • Isoniazid
  • Rifampin